Request Sample Inquiry
Diabetes Drugs Market

Diabetes Drugs Market

Diabetes Drugs Market - Global Industry Assessment & Forecast

Number Of Pages # Pages:

210

Base Year:

2024

Date

Oct - 2024

Format:

PDF XLS PPT

Report Code:

VMR-3023

Segments Covered
  • By Drug Class By Drug Class Insulin, GLP-1 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Biguanides (Metformin), Others (Thiazolidinediones, Meglitinides)
  • By Diabetes Type By Diabetes Type Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes
  • By Route of Administration By Route of Administration Oral, Injectable
  • By Distribution Channel By Distribution Channel Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Clinics
  • By Region By Region North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Snapshot
Base YearBase Year: 2024
Forecast YearsForecast Years: 2025 - 2034
Historical YearsHistorical Years: 2019 - 2023
Revenue 2024Revenue 2024: USD 84.65 Billion
Revenue 2034Revenue 2034: USD 177.74 Billion
Revenue CAGRRevenue CAGR (2025 - 2034): 7.7%
Fastest Growing Region Fastest Growing Region (2025 - 2034) Asia Pacific
Largest Region Largest Region (2024): North America
Customization Offered
  • Cross-segment Market Size and Analysis for Mentioned Segments Cross-segment Market Size and Analysis for Mentioned Segments
  • Additional Company Profiles (Upto 5 With No Cost) Additional Company Profiles (Upto 5 With No Cost)
  • Additional Countries (Apart From Mentioned Countries) Additional Countries (Apart From Mentioned Countries)
  • Country/Region-specific Report Country/Region-specific Report
  • Go To Market Strategy Go To Market Strategy
  • Region Specific Market Dynamics Region Specific Market Dynamics
  • Region Level Market Share Region Level Market Share
  • Import Export Analysis Import Export Analysis
  • Production Analysis Production Analysis
  • Other Others Request Customization Speak To Analyst
  1. Executive Dashboard
    1. Strategic Imperatives
  2. Premium Insights
    1. Top 3 Trends to Watch
    2. Demand and Supply Trends
    3. Top 3 Strategies Followed by Major Players
    4. Top 3 Predictions by Vantage Market Research
    5. Top Investment Pockets
    6. Insights from Primary Respondents
  3. Global Diabetes Drugs Market - Segment Analysis
    1. Overview
    2. Global Diabetes Drugs Market, 2016 - 2028 (USD Million)
    3. Global Diabetes Drugs Market - by Drug Class
      1. By Insulin
      2. By GLP-1 Receptor Agonists
      3. By SGLT-2 Inhibitors
      4. By DPP-4 Inhibitors
      5. By Biguanides (Metformin)
      6. By Others (Thiazolidinediones, Meglitinides)
    4. Global Diabetes Drugs Market - by Diabetes Type
      1. By Type 1 Diabetes
      2. By Type 2 Diabetes
      3. By Gestational Diabetes
    5. Global Diabetes Drugs Market - by Route of Administration
      1. By Oral
      2. By Injectable
    6. Global Diabetes Drugs Market - by Distribution Channel
      1. By Hospital Pharmacies
      2. By Retail Pharmacies
      3. By Online Pharmacies
      4. By Specialty Clinics
    7. Global Diabetes Drugs Market - by region
      1. North America
      2. Europe
      3. Asia Pacific
      4. Latin America
      5. Middle East & Africa
    8. Market comparative analysis
  4. North America Diabetes Drugs Market - Segment Analysis
    1. Overview
    2. North America Diabetes Drugs Market, 2016 - 2028 (USD Million)
    3. North America Diabetes Drugs Market, by Drug Class
      1. By Insulin
      2. By GLP-1 Receptor Agonists
      3. By SGLT-2 Inhibitors
      4. By DPP-4 Inhibitors
      5. By Biguanides (Metformin)
      6. By Others (Thiazolidinediones, Meglitinides)
    4. North America Diabetes Drugs Market, by Diabetes Type
      1. By Type 1 Diabetes
      2. By Type 2 Diabetes
      3. By Gestational Diabetes
    5. North America Diabetes Drugs Market, by Route of Administration
      1. By Oral
      2. By Injectable
    6. North America Diabetes Drugs Market, by Distribution Channel
      1. By Hospital Pharmacies
      2. By Retail Pharmacies
      3. By Online Pharmacies
      4. By Specialty Clinics
    7. North America Diabetes Drugs Market, by Country
      1. U.S.
        1. U.S. Diabetes Drugs Market, By Drug Class
          1. By Insulin
          2. By GLP-1 Receptor Agonists
          3. By SGLT-2 Inhibitors
          4. By DPP-4 Inhibitors
          5. By Biguanides (Metformin)
          6. By Others (Thiazolidinediones, Meglitinides)
        2. U.S. Diabetes Drugs Market, By Diabetes Type
          1. By Type 1 Diabetes
          2. By Type 2 Diabetes
          3. By Gestational Diabetes
        3. U.S. Diabetes Drugs Market, By Route of Administration
          1. By Oral
          2. By Injectable
        4. U.S. Diabetes Drugs Market, By Distribution Channel
          1. By Hospital Pharmacies
          2. By Retail Pharmacies
          3. By Online Pharmacies
          4. By Specialty Clinics
      2. Canada
        1. Canada Diabetes Drugs Market, By Drug Class
          1. By Insulin
          2. By GLP-1 Receptor Agonists
          3. By SGLT-2 Inhibitors
          4. By DPP-4 Inhibitors
          5. By Biguanides (Metformin)
          6. By Others (Thiazolidinediones, Meglitinides)
        2. Canada Diabetes Drugs Market, By Diabetes Type
          1. By Type 1 Diabetes
          2. By Type 2 Diabetes
          3. By Gestational Diabetes
        3. Canada Diabetes Drugs Market, By Route of Administration
          1. By Oral
          2. By Injectable
        4. Canada Diabetes Drugs Market, By Distribution Channel
          1. By Hospital Pharmacies
          2. By Retail Pharmacies
          3. By Online Pharmacies
          4. By Specialty Clinics
      3. Mexico
        1. Mexico Diabetes Drugs Market, By Drug Class
          1. By Insulin
          2. By GLP-1 Receptor Agonists
          3. By SGLT-2 Inhibitors
          4. By DPP-4 Inhibitors
          5. By Biguanides (Metformin)
          6. By Others (Thiazolidinediones, Meglitinides)
        2. Mexico Diabetes Drugs Market, By Diabetes Type
          1. By Type 1 Diabetes
          2. By Type 2 Diabetes
          3. By Gestational Diabetes
        3. Mexico Diabetes Drugs Market, By Route of Administration
          1. By Oral
          2. By Injectable
        4. Mexico Diabetes Drugs Market, By Distribution Channel
          1. By Hospital Pharmacies
          2. By Retail Pharmacies
          3. By Online Pharmacies
          4. By Specialty Clinics
  5. Europe Diabetes Drugs Market - Segment Analysis
    1. Overview
    2. Europe Diabetes Drugs Market, 2016 - 2028 (USD Million)
    3. Europe Diabetes Drugs Market, by Drug Class
      1. By Insulin
      2. By GLP-1 Receptor Agonists
      3. By SGLT-2 Inhibitors
      4. By DPP-4 Inhibitors
      5. By Biguanides (Metformin)
      6. By Others (Thiazolidinediones, Meglitinides)
    4. Europe Diabetes Drugs Market, by Diabetes Type
      1. By Type 1 Diabetes
      2. By Type 2 Diabetes
      3. By Gestational Diabetes
    5. Europe Diabetes Drugs Market, by Route of Administration
      1. By Oral
      2. By Injectable
    6. Europe Diabetes Drugs Market, by Distribution Channel
      1. By Hospital Pharmacies
      2. By Retail Pharmacies
      3. By Online Pharmacies
      4. By Specialty Clinics
    7. Europe Diabetes Drugs Market, by Country
      1. Germany
        1. Germany Diabetes Drugs Market, By Drug Class
          1. By Insulin
          2. By GLP-1 Receptor Agonists
          3. By SGLT-2 Inhibitors
          4. By DPP-4 Inhibitors
          5. By Biguanides (Metformin)
          6. By Others (Thiazolidinediones, Meglitinides)
        2. Germany Diabetes Drugs Market, By Diabetes Type
          1. By Type 1 Diabetes
          2. By Type 2 Diabetes
          3. By Gestational Diabetes
        3. Germany Diabetes Drugs Market, By Route of Administration
          1. By Oral
          2. By Injectable
        4. Germany Diabetes Drugs Market, By Distribution Channel
          1. By Hospital Pharmacies
          2. By Retail Pharmacies
          3. By Online Pharmacies
          4. By Specialty Clinics
      2. UK
        1. UK Market, By Drug Class
          1. By Insulin
          2. By GLP-1 Receptor Agonists
          3. By SGLT-2 Inhibitors
          4. By DPP-4 Inhibitors
          5. By Biguanides (Metformin)
          6. By Others (Thiazolidinediones, Meglitinides)
        2. UK Market, By Diabetes Type
          1. By Type 1 Diabetes
          2. By Type 2 Diabetes
          3. By Gestational Diabetes
        3. UK Market, By Route of Administration
          1. By Oral
          2. By Injectable
        4. UK Market, By Distribution Channel
          1. By Hospital Pharmacies
          2. By Retail Pharmacies
          3. By Online Pharmacies
          4. By Specialty Clinics
      3. France
        1. France Diabetes Drugs Market, By Drug Class
          1. By Insulin
          2. By GLP-1 Receptor Agonists
          3. By SGLT-2 Inhibitors
          4. By DPP-4 Inhibitors
          5. By Biguanides (Metformin)
          6. By Others (Thiazolidinediones, Meglitinides)
        2. France Diabetes Drugs Market, By Diabetes Type
          1. By Type 1 Diabetes
          2. By Type 2 Diabetes
          3. By Gestational Diabetes
        3. France Diabetes Drugs Market, By Route of Administration
          1. By Oral
          2. By Injectable
        4. France Diabetes Drugs Market, By Distribution Channel
          1. By Hospital Pharmacies
          2. By Retail Pharmacies
          3. By Online Pharmacies
          4. By Specialty Clinics
      4. Spain
        1. Spain Diabetes Drugs Market, By Drug Class
          1. By Insulin
          2. By GLP-1 Receptor Agonists
          3. By SGLT-2 Inhibitors
          4. By DPP-4 Inhibitors
          5. By Biguanides (Metformin)
          6. By Others (Thiazolidinediones, Meglitinides)
        2. Spain Diabetes Drugs Market, By Diabetes Type
          1. By Type 1 Diabetes
          2. By Type 2 Diabetes
          3. By Gestational Diabetes
        3. Spain Diabetes Drugs Market, By Route of Administration
          1. By Oral
          2. By Injectable
        4. Spain Diabetes Drugs Market, By Distribution Channel
          1. By Hospital Pharmacies
          2. By Retail Pharmacies
          3. By Online Pharmacies
          4. By Specialty Clinics
      5. Italy
        1. Italy Diabetes Drugs Market, By Drug Class
          1. By Insulin
          2. By GLP-1 Receptor Agonists
          3. By SGLT-2 Inhibitors
          4. By DPP-4 Inhibitors
          5. By Biguanides (Metformin)
          6. By Others (Thiazolidinediones, Meglitinides)
        2. Italy Diabetes Drugs Market, By Diabetes Type
          1. By Type 1 Diabetes
          2. By Type 2 Diabetes
          3. By Gestational Diabetes
        3. Italy Diabetes Drugs Market, By Route of Administration
          1. By Oral
          2. By Injectable
        4. Italy Diabetes Drugs Market, By Distribution Channel
          1. By Hospital Pharmacies
          2. By Retail Pharmacies
          3. By Online Pharmacies
          4. By Specialty Clinics
      6. BENELUX
        1. BENELUX Diabetes Drugs Market, By Drug Class
          1. By Insulin
          2. By GLP-1 Receptor Agonists
          3. By SGLT-2 Inhibitors
          4. By DPP-4 Inhibitors
          5. By Biguanides (Metformin)
          6. By Others (Thiazolidinediones, Meglitinides)
        2. BENELUX Diabetes Drugs Market, By Diabetes Type
          1. By Type 1 Diabetes
          2. By Type 2 Diabetes
          3. By Gestational Diabetes
        3. BENELUX Diabetes Drugs Market, By Route of Administration
          1. By Oral
          2. By Injectable
        4. BENELUX Diabetes Drugs Market, By Distribution Channel
          1. By Hospital Pharmacies
          2. By Retail Pharmacies
          3. By Online Pharmacies
          4. By Specialty Clinics
      7. Rest of Europe
        1. Rest Of Europe Diabetes Drugs Market, By Drug Class
          1. By Insulin
          2. By GLP-1 Receptor Agonists
          3. By SGLT-2 Inhibitors
          4. By DPP-4 Inhibitors
          5. By Biguanides (Metformin)
          6. By Others (Thiazolidinediones, Meglitinides)
        2. Rest Of Europe Diabetes Drugs Market, By Diabetes Type
          1. By Type 1 Diabetes
          2. By Type 2 Diabetes
          3. By Gestational Diabetes
        3. Rest Of Europe Diabetes Drugs Market, By Route of Administration
          1. By Oral
          2. By Injectable
        4. Rest Of Europe Diabetes Drugs Market, By Distribution Channel
          1. By Hospital Pharmacies
          2. By Retail Pharmacies
          3. By Online Pharmacies
          4. By Specialty Clinics
  6. Asia Pacific Diabetes Drugs Market - Segment Analysis
    1. Overview
    2. Asia Pacific Diabetes Drugs Market, 2016 - 2028 (USD Million)
    3. Asia Pacific Diabetes Drugs Market, by Drug Class
      1. By Insulin
      2. By GLP-1 Receptor Agonists
      3. By SGLT-2 Inhibitors
      4. By DPP-4 Inhibitors
      5. By Biguanides (Metformin)
      6. By Others (Thiazolidinediones, Meglitinides)
    4. Asia Pacific Diabetes Drugs Market, by Diabetes Type
      1. By Type 1 Diabetes
      2. By Type 2 Diabetes
      3. By Gestational Diabetes
    5. Asia Pacific Diabetes Drugs Market, by Route of Administration
      1. By Oral
      2. By Injectable
    6. Asia Pacific Diabetes Drugs Market, by Distribution Channel
      1. By Hospital Pharmacies
      2. By Retail Pharmacies
      3. By Online Pharmacies
      4. By Specialty Clinics
    7. Asia Pacific Diabetes Drugs Market, by Country
      1. China
        1. China Diabetes Drugs Market, By Drug Class
          1. By Insulin
          2. By GLP-1 Receptor Agonists
          3. By SGLT-2 Inhibitors
          4. By DPP-4 Inhibitors
          5. By Biguanides (Metformin)
          6. By Others (Thiazolidinediones, Meglitinides)
        2. China Diabetes Drugs Market, By Diabetes Type
          1. By Type 1 Diabetes
          2. By Type 2 Diabetes
          3. By Gestational Diabetes
        3. China Diabetes Drugs Market, By Route of Administration
          1. By Oral
          2. By Injectable
        4. China Diabetes Drugs Market, By Distribution Channel
          1. By Hospital Pharmacies
          2. By Retail Pharmacies
          3. By Online Pharmacies
          4. By Specialty Clinics
      2. Japan
        1. Japan Diabetes Drugs Market, By Drug Class
          1. By Insulin
          2. By GLP-1 Receptor Agonists
          3. By SGLT-2 Inhibitors
          4. By DPP-4 Inhibitors
          5. By Biguanides (Metformin)
          6. By Others (Thiazolidinediones, Meglitinides)
        2. Japan Diabetes Drugs Market, By Diabetes Type
          1. By Type 1 Diabetes
          2. By Type 2 Diabetes
          3. By Gestational Diabetes
        3. Japan Diabetes Drugs Market, By Route of Administration
          1. By Oral
          2. By Injectable
        4. Japan Diabetes Drugs Market, By Distribution Channel
          1. By Hospital Pharmacies
          2. By Retail Pharmacies
          3. By Online Pharmacies
          4. By Specialty Clinics
      3. India
        1. India Diabetes Drugs Market, By Drug Class
          1. By Insulin
          2. By GLP-1 Receptor Agonists
          3. By SGLT-2 Inhibitors
          4. By DPP-4 Inhibitors
          5. By Biguanides (Metformin)
          6. By Others (Thiazolidinediones, Meglitinides)
        2. India Diabetes Drugs Market, By Diabetes Type
          1. By Type 1 Diabetes
          2. By Type 2 Diabetes
          3. By Gestational Diabetes
        3. India Diabetes Drugs Market, By Route of Administration
          1. By Oral
          2. By Injectable
        4. India Diabetes Drugs Market, By Distribution Channel
          1. By Hospital Pharmacies
          2. By Retail Pharmacies
          3. By Online Pharmacies
          4. By Specialty Clinics
      4. South Korea
        1. South Korea Diabetes Drugs Market, By Drug Class
          1. By Insulin
          2. By GLP-1 Receptor Agonists
          3. By SGLT-2 Inhibitors
          4. By DPP-4 Inhibitors
          5. By Biguanides (Metformin)
          6. By Others (Thiazolidinediones, Meglitinides)
        2. South Korea Diabetes Drugs Market, By Diabetes Type
          1. By Type 1 Diabetes
          2. By Type 2 Diabetes
          3. By Gestational Diabetes
        3. South Korea Diabetes Drugs Market, By Route of Administration
          1. By Oral
          2. By Injectable
        4. South Korea Diabetes Drugs Market, By Distribution Channel
          1. By Hospital Pharmacies
          2. By Retail Pharmacies
          3. By Online Pharmacies
          4. By Specialty Clinics
      5. South East Asia
        1. South East Asia Diabetes Drugs Market, By Drug Class
          1. By Insulin
          2. By GLP-1 Receptor Agonists
          3. By SGLT-2 Inhibitors
          4. By DPP-4 Inhibitors
          5. By Biguanides (Metformin)
          6. By Others (Thiazolidinediones, Meglitinides)
        2. South East Asia Diabetes Drugs Market, By Diabetes Type
          1. By Type 1 Diabetes
          2. By Type 2 Diabetes
          3. By Gestational Diabetes
        3. South East Asia Diabetes Drugs Market, By Route of Administration
          1. By Oral
          2. By Injectable
        4. South East Asia Diabetes Drugs Market, By Distribution Channel
          1. By Hospital Pharmacies
          2. By Retail Pharmacies
          3. By Online Pharmacies
          4. By Specialty Clinics
      6. Rest of Asia Pacific
        1. Rest of Asia Pacific Diabetes Drugs Market, By Drug Class
          1. By Insulin
          2. By GLP-1 Receptor Agonists
          3. By SGLT-2 Inhibitors
          4. By DPP-4 Inhibitors
          5. By Biguanides (Metformin)
          6. By Others (Thiazolidinediones, Meglitinides)
        2. Rest of Asia Pacific Diabetes Drugs Market, By Diabetes Type
          1. By Type 1 Diabetes
          2. By Type 2 Diabetes
          3. By Gestational Diabetes
        3. Rest of Asia Pacific Diabetes Drugs Market, By Route of Administration
          1. By Oral
          2. By Injectable
        4. Rest of Asia Pacific Diabetes Drugs Market, By Distribution Channel
          1. By Hospital Pharmacies
          2. By Retail Pharmacies
          3. By Online Pharmacies
          4. By Specialty Clinics
  7. Latin America Diabetes Drugs Market - Segment Analysis
    1. Overview
    2. Latin America Diabetes Drugs Market, 2016 - 2028 (USD Million)
    3. Latin America Diabetes Drugs Market, by Drug Class
      1. By Insulin
      2. By GLP-1 Receptor Agonists
      3. By SGLT-2 Inhibitors
      4. By DPP-4 Inhibitors
      5. By Biguanides (Metformin)
      6. By Others (Thiazolidinediones, Meglitinides)
    4. Latin America Diabetes Drugs Market, by Diabetes Type
      1. By Type 1 Diabetes
      2. By Type 2 Diabetes
      3. By Gestational Diabetes
    5. Latin America Diabetes Drugs Market, by Route of Administration
      1. By Oral
      2. By Injectable
    6. Latin America Diabetes Drugs Market, by Distribution Channel
      1. By Hospital Pharmacies
      2. By Retail Pharmacies
      3. By Online Pharmacies
      4. By Specialty Clinics
    7. Latin America Diabetes Drugs Market, by Country
      1. Brazil
        1. Brazil Diabetes Drugs Market, By Drug Class
          1. By Insulin
          2. By GLP-1 Receptor Agonists
          3. By SGLT-2 Inhibitors
          4. By DPP-4 Inhibitors
          5. By Biguanides (Metformin)
          6. By Others (Thiazolidinediones, Meglitinides)
        2. Brazil Diabetes Drugs Market, By Diabetes Type
          1. By Type 1 Diabetes
          2. By Type 2 Diabetes
          3. By Gestational Diabetes
        3. Brazil Diabetes Drugs Market, By Route of Administration
          1. By Oral
          2. By Injectable
        4. Brazil Diabetes Drugs Market, By Distribution Channel
          1. By Hospital Pharmacies
          2. By Retail Pharmacies
          3. By Online Pharmacies
          4. By Specialty Clinics
      2. Argentina
        1. Argentina Diabetes Drugs Market, By Drug Class
          1. By Insulin
          2. By GLP-1 Receptor Agonists
          3. By SGLT-2 Inhibitors
          4. By DPP-4 Inhibitors
          5. By Biguanides (Metformin)
          6. By Others (Thiazolidinediones, Meglitinides)
        2. Argentina Diabetes Drugs Market, By Diabetes Type
          1. By Type 1 Diabetes
          2. By Type 2 Diabetes
          3. By Gestational Diabetes
        3. Argentina Diabetes Drugs Market, By Route of Administration
          1. By Oral
          2. By Injectable
        4. Argentina Diabetes Drugs Market, By Distribution Channel
          1. By Hospital Pharmacies
          2. By Retail Pharmacies
          3. By Online Pharmacies
          4. By Specialty Clinics
      3. Rest of Latin America
        1. Rest of Latin America Diabetes Drugs Market, By Drug Class
          1. By Insulin
          2. By GLP-1 Receptor Agonists
          3. By SGLT-2 Inhibitors
          4. By DPP-4 Inhibitors
          5. By Biguanides (Metformin)
          6. By Others (Thiazolidinediones, Meglitinides)
        2. Rest of Latin America Diabetes Drugs Market, By Diabetes Type
          1. By Type 1 Diabetes
          2. By Type 2 Diabetes
          3. By Gestational Diabetes
        3. Rest of Latin America Diabetes Drugs Market, By Route of Administration
          1. By Oral
          2. By Injectable
        4. Rest of Latin America Diabetes Drugs Market, By Distribution Channel
          1. By Hospital Pharmacies
          2. By Retail Pharmacies
          3. By Online Pharmacies
          4. By Specialty Clinics
  8. Middle East & Africa Diabetes Drugs Market - Segment Analysis
    1. Overview
    2. Middle East & Africa Diabetes Drugs Market, 2016 - 2028 (USD Million)
    3. Middle East & Africa Diabetes Drugs Market, by Drug Class
      1. By Insulin
      2. By GLP-1 Receptor Agonists
      3. By SGLT-2 Inhibitors
      4. By DPP-4 Inhibitors
      5. By Biguanides (Metformin)
      6. By Others (Thiazolidinediones, Meglitinides)
    4. Middle East & Africa Diabetes Drugs Market, by Diabetes Type
      1. By Type 1 Diabetes
      2. By Type 2 Diabetes
      3. By Gestational Diabetes
    5. Middle East & Africa Diabetes Drugs Market, by Route of Administration
      1. By Oral
      2. By Injectable
    6. Middle East & Africa Diabetes Drugs Market, by Distribution Channel
      1. By Hospital Pharmacies
      2. By Retail Pharmacies
      3. By Online Pharmacies
      4. By Specialty Clinics
    7. Middle East & Africa Diabetes Drugs Market, by Country
      1. GCC Countries
        1. GCC Countries Diabetes Drugs Market, By Drug Class
          1. By Insulin
          2. By GLP-1 Receptor Agonists
          3. By SGLT-2 Inhibitors
          4. By DPP-4 Inhibitors
          5. By Biguanides (Metformin)
          6. By Others (Thiazolidinediones, Meglitinides)
        2. GCC Countries Diabetes Drugs Market, By Diabetes Type
          1. By Type 1 Diabetes
          2. By Type 2 Diabetes
          3. By Gestational Diabetes
        3. GCC Countries Diabetes Drugs Market, By Route of Administration
          1. By Oral
          2. By Injectable
        4. GCC Countries Diabetes Drugs Market, By Distribution Channel
          1. By Hospital Pharmacies
          2. By Retail Pharmacies
          3. By Online Pharmacies
          4. By Specialty Clinics
      2. South Africa
        1. South Africa Diabetes Drugs Market, By Drug Class
          1. By Insulin
          2. By GLP-1 Receptor Agonists
          3. By SGLT-2 Inhibitors
          4. By DPP-4 Inhibitors
          5. By Biguanides (Metformin)
          6. By Others (Thiazolidinediones, Meglitinides)
        2. South Africa Diabetes Drugs Market, By Diabetes Type
          1. By Type 1 Diabetes
          2. By Type 2 Diabetes
          3. By Gestational Diabetes
        3. South Africa Diabetes Drugs Market, By Route of Administration
          1. By Oral
          2. By Injectable
        4. South Africa Diabetes Drugs Market, By Distribution Channel
          1. By Hospital Pharmacies
          2. By Retail Pharmacies
          3. By Online Pharmacies
          4. By Specialty Clinics
      3. Rest of Middle East & Africa
        1. Rest of Middle East & Africa Diabetes Drugs Market, By Drug Class
          1. By Insulin
          2. By GLP-1 Receptor Agonists
          3. By SGLT-2 Inhibitors
          4. By DPP-4 Inhibitors
          5. By Biguanides (Metformin)
          6. By Others (Thiazolidinediones, Meglitinides)
        2. Rest of Middle East & Africa Diabetes Drugs Market, By Diabetes Type
          1. By Type 1 Diabetes
          2. By Type 2 Diabetes
          3. By Gestational Diabetes
        3. Rest of Middle East & Africa Diabetes Drugs Market, By Route of Administration
          1. By Oral
          2. By Injectable
        4. Rest of Middle East & Africa Diabetes Drugs Market, By Distribution Channel
          1. By Hospital Pharmacies
          2. By Retail Pharmacies
          3. By Online Pharmacies
          4. By Specialty Clinics
  9. Key Market Dynamics
    1. Introduction
    2. Market Drivers
    3. Market Restraints
    4. Market Opportunities
    5. Porter's Five Forces Analysis
    6. PEST Analysis
    7. Regulatory Landscape
    8. Technology Landscape
    9. Regional Market Trends
  10. COVID 19 Impact Analysis
    1. Key strategies undertaken by companies to tackle COVID-19
    2. Short term dynamics
    3. Long term dynamics
  11. Marketing Stratagy Analysis
    1. Marketing Channel
    2. Direct Marketing
    3. Indirect Marketing
    4. Marketing Channel Development Trends
  12. Competative Landscape
    1. Competition Matrix - 2021
    2. Company Market Share Analysis - 2021
    3. Key Company Activities, 2018 - 2021
    4. Strategic Developments - Heat Map Analysis
    5. Company Offering Evaluation
    6. Company Regional Presence Evaluation
  13. Company Profiles
    1. Novo Nordisk
    2. Sanofi
    3. Bristol Myers Squibb
    4. Eli Lilly and Company
    5. AstraZeneca
    6. Merck & Co.
    7. Johnson & Johnson
    8. Pfizer
    9. Novartis
    10. Boehringer Ingelheim
    11. AbbVie
    12. Teva Pharmaceuticals
    13. Glenmark Pharmaceuticals
    14. Lupin Pharmaceuticals
    15. Mylan N.V. (now part of Viatris).
  14. Key Primary Respondents - VERBATIM
  15. Discussion Guide
  16. Customization Offered
  17. Annexure
  18. List of Figures
  19. List of Tables
  20. List of Abbreviations
FAQ
Frequently Asked Question
  • The global Diabetes Drugs valued at USD 84.65 Billion in 2024 and is expected to reach USD 177.74 Billion in 2034 growing at a CAGR of 7.7%.

  • The prominent players in the market are Novo Nordisk, Sanofi, Bristol Myers Squibb, Eli Lilly and Company, AstraZeneca, Merck & Co., Johnson & Johnson, Pfizer, Novartis, Boehringer Ingelheim, AbbVie, Teva Pharmaceuticals, Glenmark Pharmaceuticals, Lupin Pharmaceuticals, Mylan N.V. (now part of Viatris)..

  • The market is project to grow at a CAGR of 7.7% between 2025 and 2034.

  • The driving factors of the Diabetes Drugs include

  • North America was the leading regional segment of the Diabetes Drugs in 2024.